Polypharmacology of S-1117, an Fc-fused IgG-selective degrading enzyme, for chronic treatment of autoantibody-mediated diseases - PubMed
6 hours ago
- #IgG cleavage
- #Polypharmacology
- #Autoimmune disease
- S-1117 is an engineered IgG-cleaving enzyme fused to a human Fc domain for extended half-life.
- It reduces immunogenicity and has pharmacokinetic and manufacturability properties similar to monoclonal antibodies.
- S-1117 cleaves IgG, lowering pathogenic autoantibodies and immune complexes, and reduces effector functions like complement fixation.
- The polypharmacology includes cleaving antigen receptors on IgG-positive memory B cells to modulate their activation.
- It addresses limitations of existing therapies for autoantibody-mediated diseases such as safety, efficacy, and convenience issues.